Degarelix
Degarelix (Firmagon) is a 10-aa GnRH receptor antagonist that suppresses testosterone to castrate levels within 3 days without the initial flare of GnRH agonists. FDA-approved for advanced prostate cancer.
Community Rating
No ratings yet
Compound Profile
Degarelix
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Degarelix is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Rapid testosterone suppression to castrate levels (<50 ng/dL) within 3 days — eliminates the 2-4 week delay of GnRH agonist therapy
- No testosterone flare — immediate competitive GnRH receptor blockade; no need for prophylactic antiandrogen
- FDA-approved for advanced prostate cancer (androgen deprivation therapy)
- Degarelix is not FDA-approved for human use. FDA-approved prescription drug (Firmagon, Ferring Pharmaceuticals). Indicated for advanced prostate cancer. Prescription required.
Research At a Glance
- Rapid testosterone suppression to castrate levels (<50 ng/dL) within 3 days — eliminates the 2-4 week delay of GnRH agonist therapy
- No testosterone flare — immediate competitive GnRH receptor blockade; no need for prophylactic antiandrogen
- FDA-approved for advanced prostate cancer (androgen deprivation therapy)
- Potential cardiovascular advantage vs GnRH agonists — pooled analyses suggest lower MACE rates (MACE = major adverse cardiovascular events)
In Plain English
Simple summaryDegarelix (Firmagon) is a GnRH antagonist -- unlike leuprolide and triptorelin which are agonists that produce suppression through receptor desensitization, degarelix directly blocks GnRH receptors and produces immediate testosterone suppression within 1-3 days, without the initial testosterone surge (flare) that agonists cause. This distinction matters clinically: in prostate cancer patients with bone metastases or spinal cord compression, a temporary testosterone flare from agonist initiation can cause dangerous worsening of symptoms. Degarelix avoids this. FDA-approved in 2008 for advanced prostate cancer, it's given as monthly subcutaneous injections in the abdominal area.
- Rapid testosterone suppression to castrate levels (<50 ng/dL) within 3 days — eliminates the 2-4 week delay of GnRH agonist therapy
- No testosterone flare — immediate competitive GnRH receptor blockade; no need for prophylactic antiandrogen
- FDA-approved for advanced prostate cancer
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Degarelix?
Tap any underlined term for an instant definition.
Degarelix (brand name: Firmagon) is a synthetic 10-amino acid GnRH receptor antagonist developed by Ferring Pharmaceuticals. It received FDA approval in 2008 for the treatment of advanced prostate cancer, offering an alternative to GnRH agonist therapy (leuprolide, goserelin) without the testosterone flare.
Degarelix was designed as a third-generation GnRH antagonist, optimizing upon earlier antagonists (cetrorelix, ganirelix) specifically for the subcutaneous depot formulation required for long-term prostate cancer therapy. Key structural modifications include D-amino acid substitutions at multiple positions and a unique C-terminal modification that reduces histamine release (a problem with first-generation GnRH antagonists).
**Mechanism — competitive antagonist without flare:** Degarelix competitively blocks GnRH receptors in the anterior pituitary within hours of injection: 1. Hour 1-24: Rapid LH and FSH suppression as GnRH receptor blockade takes effect 2. Day 1-3: Testosterone falls to castrate levels (<50 ng/dL in >95% of patients by day 3) 3. No initial testosterone surge — in contrast, GnRH agonists initially stimulate testosterone for 1-2 weeks before suppression
The SC depot forms a gel-like depot at the injection site from which degarelix is slowly released, providing approximately 28 days of sustained GnRH receptor blockade per 80 mg dose.
**Cardiovascular controversy:** Multiple pooled analyses and registry studies (including a meta-analysis by Albertsen et al.) have suggested that degarelix is associated with fewer major adverse cardiovascular events (MACE) vs GnRH agonists in men with pre-existing cardiovascular disease. The proposed mechanism relates to FSH's direct cardiovascular effects (GnRH agonists transiently elevate FSH via the flare before suppression), but the evidence is not from a randomized trial. The PRONOUNCE trial (NCT02663908) was designed to prospectively compare MACE rates but was terminated early due to low event rates.
**CS21 Phase III trial (Klotz et al.):** In 610 treatment-naive prostate cancer patients, degarelix 240/80 mg achieved testosterone <50 ng/dL in 95% of patients by day 3, vs 0% of leuprolide patients (who showed testosterone flare). By day 28, both groups achieved similar castrate rates.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Degarelix. See all Hormonal Health peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Degarelix (Firmagon) dosing for prostate cancer:
Loading dose: 240 mg SC (given as two 120 mg injections in the abdominal area) Maintenance dose: 80 mg SC once monthly (beginning 28 days after loading dose) Injection site: Abdominal SC fat; avoid areas near the belt line PSA monitoring: every 3 months; testosterone monitoring to confirm castrate levels
Duration: Long-term continuous therapy while prostate cancer is active
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
SC injection into the abdominal area (not IM like GnRH agonist depots). Reconstitute the powder with the provided diluent using the specific reconstitution technique (swirl gently, do not shake). Inject the thick depot solution slowly.
What the research doesn't show
Degarelix's injectable format (abdominal subcutaneous injections) produces notable injection site reactions in many patients -- a practical tolerability issue that has driven interest in oral alternatives like relugolix. The cardiovascular benefit signal from meta-analyses is intriguing but not definitively established; it hasn't changed FDA labeling. The field is moving toward oral GnRH antagonists but degarelix remains widely used.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Degarelix, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Degarelix has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: rapid testosterone suppression to castrate levels (<50 ng/dl) within 3 days — eliminates the 2-4 week delay of gnrh agonist therapy.
The most commonly reported side effect in research subjects is injection site reactions in >35% of patients — more common than with gnrh agonist depots. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Leuprolide and triptorelin are GnRH agonists with the same eventual testosterone suppression but different kinetics and the flare problem. Relugolix (Orgovyx) is an oral GnRH antagonist that has the same flare-free rapid suppression as degarelix with the additional advantage of reversibility -- testosterone recovers faster after stopping. Degarelix's limitation is injection site reactions (pain, redness) that oral relugolix avoids.
Compare Degarelix side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.